Beuche, Wolfgang

[["dc.bibliographiccitation.firstpage","82"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","The Laryngoscope"],["dc.bibliographiccitation.lastpage","86"],["dc.bibliographiccitation.volume","112"],["dc.contributor.author","Ellies, M."],["dc.contributor.author","Laskawi, Rainer"],["dc.contributor.author","Rohrbach-Volland, S."],["dc.contributor.author","Arglebe, C."],["dc.contributor.author","Beuche, W."],["dc.date.accessioned","2018-11-07T10:33:25Z"],["dc.date.available","2018-11-07T10:33:25Z"],["dc.date.issued","2002"],["dc.description.abstract","Objectives/Hypothesis: The study investigates the effect of local injections of botulinum. toxin type A (Botox) into the major salivary glands of the head in various states of hypersalivation. In particular, we studied pathological states with permanent as well as passing hypersalivation disorders and present new indications for local application of botulinum. toxin to the salivary glands. Study Design: Retrospective clinical investigation. Methods: A total of 55 to 65 units of Botox were injected under sonographic control into the left and right parotid and submandibular glands of four patients with hypersalivation resulting from head and neck carcinoma, tracheostomy, and \"idiopathic\" hypersalivation disorder. At defined time intervals following injection, flow rate, total protein and immunoglobulin A content, and the enzymatic activities of amylase, acid phosphatase, and kallikrein were determined in the saliva. The patients were clinically examined to assess the severity of their symptoms, including sonographic control of the major salivary glands. Results: All four patients reported distinct improvement of their symptoms within 1 week after injection. Salivary flow rate had considerably dropped, whereas the concentrations of the salivary components were much increased. Sonography did not reveal any changes of the salivary gland parenchyma. Therapeutic side effects were absent. Conclusions: Treatment of hypersalivation by local injections of Botox into the salivary glands of the head is a reliable and efficient therapy without side effects for certain otolaryngological diseases, especially if injections are performed under sonographic control. Extension of this therapeutic concept to other indications is suggested."],["dc.identifier.doi","10.1097/00005537-200201000-00015"],["dc.identifier.isi","000173415300015"],["dc.identifier.pmid","11802043"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44607"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0023-852X"],["dc.title","Botulinum toxin to reduce saliva flow: Selected indications for ultrasound-guided toxin application into salivary glands"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","807"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","HNO"],["dc.bibliographiccitation.lastpage","+"],["dc.bibliographiccitation.volume","49"],["dc.contributor.author","Ellies, M."],["dc.contributor.author","Laskawi, Rainer"],["dc.contributor.author","Rohrbach-Volland, S."],["dc.contributor.author","Rodel, R."],["dc.contributor.author","Beuche, W."],["dc.date.accessioned","2018-11-07T08:35:19Z"],["dc.date.available","2018-11-07T08:35:19Z"],["dc.date.issued","2001"],["dc.description.abstract","Background. Hypersecretion disorders of the exocrine glands of the head and neck area are a therapeutic problem in the field of otorhinolaryngology. In the present study, we demonstrate the effectiveness of local injections of botulinum toxin A to block secretions of exocrine glands of the head and neck area. Patients and methods. Four patients suffering from hypersecretion disorders received local injections of botulinum toxin A to patients suffered from disorders of the salivary glands: one presented an idiopathic hypersialorrhea and another a salivary fistula after parotidectomy. A third patient suffered from epiphora and a further patient presented severe hyperhidrosis on the pilose head region. In a retrospective clinical study, the outcome of therapy was evaluated by clinical examination and chemical parameters. Results. Clear blocking of secretion in the treated glands could be demonstrated in all four cases. Possible side effects of the treatment could not be observed. Conclusions. The present study was able to demonstrate a clear blocking of secretion of the exocrine glands of the head and neck region through botulinum toxin A, offering an improvement in therapy especially for the innovative indication of blocking the salivary glands of the head."],["dc.identifier.doi","10.1007/s001060170028"],["dc.identifier.isi","000171616600001"],["dc.identifier.pmid","11699140"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18036"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0017-6192"],["dc.title","Blocking of secretion in exocrine glands of the head and neck area with botulinum toxin A. Therapeutic option in the treatment of rare diseases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","23"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH"],["dc.bibliographiccitation.lastpage","26"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Beuche, W."],["dc.contributor.author","Arglebe, C."],["dc.contributor.author","Laskawi, Rainer"],["dc.date.accessioned","2018-11-07T11:12:46Z"],["dc.date.available","2018-11-07T11:12:46Z"],["dc.date.issued","2000"],["dc.description.abstract","A quantitative reduction of saliva production to less than 10% of original flow rate could be achieved by intraglandular injections of a total of 300 units of botulinum toxin (type DysportR) in two amyotrophic lateral sclerosis (ALS) patients. The treatment effect lasted for at least 8 weeks and increased after repeated injections. All major salivary glands were injected. Masseter strength did not decrease intolerably. This treatment can therefore be recommended even in ALS patients with paresis of the bulbar musculature."],["dc.identifier.isi","000167324800004"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53735"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Universitatsverlag Ulm Gmbh"],["dc.relation.issn","0941-9500"],["dc.title","Quantitative reduction of saliva production in two ALS patients with intraglandular injections of botulinum toxin."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]